Search

Author/Creator Ferry, D

1. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. (28th December 2019)

Authors:
Yoon, H H; Bendell, J C; Braiteh, F S; Firdaus, I; Philip, P A; Cohn, A L; Lewis, N; Anderson, D M; Arrowsmith, E; Schwartz, J D; Gao, L; Hsu, Y; Xu, Y; Ferry, D; Alberts, S R; Wainberg, Z A
Journal:
Annals of oncology
Issue:
Volume 30:Number 12(2019)
Page Start:
2016
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC. (2nd December 2011)

Authors:
Ferry, D; Billingham, L J; Jarrett, H W; Dunlop, D; Thompson, J; Kumar, M; Skailes, G; Nicolson, M; Shah, R; Leonard, P; Chetiyawardana, A; Wells, P; Lewanski, C; Woll, P; Crosse, B; Hill, M; Pirrie, S; O'Byrne, K J
Journal:
Thorax
Issue:
Volume 66(2011)Supplement 4
Page Start:
A41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. S86 Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients. (2nd December 2011)

Authors:
Billingham, L J; Gaunt, P; Jarrett, H W; Dunlop, D; Thompson, J; O'Byrne, K J; Kumar, M; Skailes, G; Nicolson, M; Shah, R; Leonard, P; Chetiyawardana, A; Wells, P; Lewanski, C; Woll, P; Crosse, B; Hill, M; Ferry, D
Journal:
Thorax
Issue:
Volume 66(2011)Supplement 4
Page Start:
A41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. S87 Delivered dose intensity of gemcitabine 1250 mg/m2 with cisplatin at 80 mg/m2 (GC80) and 50 mg/m2 (GC50) and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC): correlations with clinical outcomes. (2nd December 2011)

Authors:
Dunlop, D; Ferry, D; Jarrett, H W; Billingham, L J; Thompson, J; Kumar, M; Skailes, G; Nicolson, M; Shah, R; Leonard, P; Chetiyawardana, A; Wells, P; Lewanski, C; Woll, P; Crosse, B; O'Byrne, K J
Journal:
Thorax
Issue:
Volume 66(2011)Supplement 4
Page Start:
A41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. SO-002Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). (2nd July 2019)

Authors:
Chau, I; Bendell, J; Soriano, A; Arkenau, H; Cultrera, J; Santana-Davila, R; Calvo, E; Tourneau, C Le; Zender, L; Mi, G; Schelman, W; Ferry, D; Herbst, R; Fuchs, C
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗